The development of accurate diagnostic technologies for Alzheimer's disease (AD) has become a critical area of investment and innovation. As the field moves toward earlier detection and intervention, companies are developing sophisticated tools including PET/SPECT radiotracers, blood-based biomarkers, and artificial intelligence-powered diagnostic platforms. This page provides a comprehensive directory of companies actively developing diagnostic technologies for AD[1].
The AD diagnostic market has undergone significant transformation with the approval of disease-modifying therapies like Leqembi (lecanemab) and Donanemab, which have increased demand for accurate diagnostic tools to identify patients who may benefit from treatment. The global AD diagnostic market is projected to grow substantially through the decade, driven by:
| Company | Product | Target | Status |
|---|---|---|---|
| Life Molecular Imaging | Neuraceq® (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2014) |
| Avid Radiopharmaceuticals | Amyvid (Florbetapir F-18) | Beta-amyloid plaques | FDA approved (2012) |
| GE Healthcare | Naviqi (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2020) |
| Piramal Imaging | NeuraCeq (Florbetaben F-18) | Beta-amyloid plaques | FDA approved (2014) |
Life Molecular Imaging is a German company specializing in PET tracer development, acquired by Lantheus Holdings in 2024. Their lead product Neuraceq® provides amyloid plaque imaging for AD diagnosis[3].
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, developed Amyvid, the first FDA-approved amyloid PET tracer. The company continues to develop next-generation imaging agents[4].
| Company | Product | Target | Status |
|---|---|---|---|
| Avid Radiopharmaceuticals | Tauvid (Flortaucipir F-18) | Tau neurofibrillary tangles | FDA approved (2020) |
| Life Molecular Imaging | LMI 119 | Tau protein | Phase 2 |
| Cerveau Technologies | MK-6240 | Tau tangles | Phase 3 |
| Pinteon Therapeutics | PINTon | Tau aggregates | Phase 1 |
Cerveau Technologies is developing MK-6240, a next-generation tau PET tracer that shows improved binding characteristics compared to first-generation tracers. The tracer has completed Phase 3 trials and is under FDA review[5].
Pinteon Therapeutics focuses on tau-targeted imaging and therapeutic approaches, leveraging their understanding of tau oligomerization in AD pathogenesis[6].
| Company | Product | Target | Development Stage |
|---|---|---|---|
| Life Molecular Imaging | LMI 115 | Alpha-synuclein | Preclinical |
| AC Immune | ACI-35 | Alpha-synuclein | Phase 1 |
| Prothena | PRX004 | Alpha-synuclein | Phase 1 |
Imaging alpha-synuclein pathology remains challenging due to the protein's unique structure. Several companies are developing PET tracers for Parkinson's disease and related disorders, which will also benefit AD research[7].
The emergence of blood-based biomarkers represents a paradigm shift in AD diagnostics, offering accessible, cost-effective testing compared to PET imaging or cerebrospinal fluid (CSF) analysis.
| Company | Key Products | Biomarkers |
|---|---|---|
| Quanterix | Simoa® platform | p-tau181, p-tau217, NFL |
| Fujirebio | Lumipulse® G | p-tau181, p-tau217, t-tau, Aβ42/40 |
| Roche | Elecsys® | p-tau181, p-tau217, NFL |
| Diadem | PreCODE® test | Blood-based panels |
| C2N Diagnostics | PrecivityAD® | Aβ42/40 ratio, p-tau181 |
Quanterix has pioneered ultra-sensitive biomarker detection using their Simoa® (Single Molecule Array) technology, enabling detection of proteins at femtogram levels. Their platform is used extensively in AD research and clinical trials[8].
Fujirebio offers the Lumipulse G platform for automated measurement of AD biomarkers in CSF and plasma, including p-tau181 and p-tau217[9].
Roche has developed the Elecsys® portfolio of AD biomarkers, with plasma p-tau181 receiving FDA clearance for use in clinical settings. Their partnership with Biogen on the AD diagnostic platform has accelerated adoption[10].
| Company | Focus Area | Differentiation |
|---|---|---|
| Altus | p-tau217 assays | High-throughput platform |
| Sysmex | AI-integrated diagnostics | Automated analysis |
| Seegene | Multiplex panels | Syndromic testing |
C2N Diagnostics offers the PrecivityAD® blood test, which measures Aβ42/40 ratio and p-tau181 to assess amyloid and tau pathology. The test is available through physician ordering in the United States[11].
Artificial intelligence and machine learning are transforming AD diagnosis through automated analysis of imaging data, integration of multimodal biomarkers, and predictive modeling.
| Company | Product | Application |
|---|---|---|
| icometrix | icobrain | MRI analysis for AD |
| BrainSee | BrainSee test | Predictive diagnostic |
| NeuroPace | RNS System | Neural signal analysis |
| Cogniview | CogniVue | Cognitive assessment |
icometrix provides icobrain, an AI-powered software that automatically quantifies brain atrophy from MRI scans and supports diagnosis of AD and other neurodegenerative conditions[12].
BrainSee has developed a predictive diagnostic test that combines AI analysis of brain MRI with clinical assessments to predict progression from mild cognitive impairment (MCI) to AD[13].
| Company | Platform | Function |
|---|---|---|
| CogniFit | BrainHQ | Cognitive training and assessment |
| Akili Interactive | EndeavorRx | Digital therapeutics |
| Pear Therapeutics | reSET | Prescription digital therapeutics |
| Company | Country | Focus |
|---|---|---|
| Life Molecular Imaging | Germany | PET tracers |
| ibiD | Netherlands | Blood biomarkers |
| Nordic Bioscience | Denmark | Biomarker assays |
| Company | Country | Focus |
|---|---|---|
| Fujifilm | Japan | Diagnostic imaging |
| Hitachi | Japan | PET systems |
| Siemens Healthineers | Japan/Germany | Imaging AI |
| Shimadzu | Japan | Diagnostic equipment |
Fujifilm has expanded into AI-powered diagnostic imaging, developing systems that integrate with their broad portfolio of medical imaging equipment[14].
| Modality | Cost | Accessibility | Accuracy (AD) |
|---|---|---|---|
| Amyloid PET | High | Limited | High |
| Tau PET | High | Limited | High |
| Blood biomarkers | Low | Widely available | Moderate-High |
| CSF biomarkers | Moderate | Limited | High |
| MRI + AI | Moderate | Widely available | Moderate |
| Biomarker | Aβ Status | Tau Status | Clinical Utility |
|---|---|---|---|
| p-tau181 | + | ++ | Early detection |
| p-tau217 | +++ | +++ | High correlation |
| p-tau231 | ++ | + | Preclinical |
| NFL | - | + | Progression |
| Aβ42/40 | +++ | - | Core biomarker |
Major pharmaceutical companies have invested significantly in diagnostic capabilities to support their therapeutic portfolios: